Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • ‘We’re going to fight until the end’: FBI Mar-a-Lago raid fires up Trump’s base
    • Military briefing: Crimea explosions focus spotlight on shadow counter-offensive
    • Fed’s Mary Daly says it is too early to ‘declare victory’ on inflation fight
    • US justice department moves to unseal warrant for search of Trump residence
    • Olaf Scholz backs proposal for new European gas pipeline
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Ping An doubles down on campaign to break up HSBC
      • Lay-offs during a jobs boom: the paradox of the US labour market
      • Carmakers’ battery plans in peril as raw material costs soar
      • London’s Groucho Club sold for £40mn
      • Credit Suisse steps up legal claim against SoftBank in $440mn dispute
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      • Cryptofinance
      Most Read
      • Live news updates from August 11: European electricity prices hit record high, Argentina lifts rates to 69.5%
      • Western sanctions have had ‘limited impact’ on Russian oil output, says IEA
      • Nasdaq rallies more than 20% from recent lows after US inflation eases
      • Two former JPMorgan metals traders convicted at spoofing trial
      • Bank of England warns Truss and Sunak over City regulation plans
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Mortgage wake-up call for middle classes
      • Russia’s diplomats are now reduced to propagandists
      • In praise of boredom
      • Germany is now the fulcrum for Vladimir Putin’s pressure
      • Companies are struggling to adjust as consumers go cold on goods
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Can a city be redesigned for the new world of work?
      • Brompton’s Will Butler-Adams: ‘People have no idea what goes into a product. That’s not a good thing’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Britain’s housing crisis — no longer a nation of homeowners?
      • The Greek brand making mythology look modern
      • A €1 dream scheme sparks a wider homebuying trend in Sicily
      • Why computers in the classroom need a reboot
      • Glyndebourne’s Poulenc double bill contrasts ideas of womanhood — review
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Your guide to a disrupted world

    Start a 4-week trial

    AstraZeneca PLC

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Saturday, 30 July, 2022
      AstraZeneca to double number of countries where US biotech arm sells rare disease drugs

      Anglo-Swedish pharmaceutical group wants to capitalise on its $39bn acquisition of Alexion

    • Friday, 29 July, 2022
      AstraZeneca raises forecasts after strong Covid and cancer drug sales

      Chief executive says revenue rise will allow drugmaker to boost investment in R&D

    • Tuesday, 19 July, 2022
      LexCovid-19 vaccines
      Covid-19 vaccines: shape-shifting virus puts agile manufacturers at an advantage Premium content

      The latest strains have spread fast and governments are trying to catch up

    • Friday, 1 July, 2022
      Covid-19 vaccines
      Oxford BioMedica extends Covid vaccine deal with AstraZeneca

      New three-year contract in place if UK drugmaker continues to manufacture the jab

    • Wednesday, 22 June, 2022
      Covid-19 vaccines
      UK signs £1bn deal with Moderna for new vaccine centre

      Government seeks to secure domestic jab supply and prepare for future pandemics in deal with Boston biotech

    • Sunday, 5 June, 2022
      Medical science
      AstraZeneca-Daiichi drug sharply raises breast cancer survival rate, trial shows

      Doctors hopeful antibody therapy could change treatment for most common type of late-stage breast cancer

    • Friday, 29 April, 2022
      AstraZeneca sales beat forecasts on Covid jab demand

      Revenue rises 60% as Alexion acquisition and its rare diseases medicines boost drugmaker’s earnings

    • Wednesday, 20 April, 2022
      Oxford BioMedica PLC
      Oxford BioMedica warns revenue will be hit by AstraZeneca jab uncertainty

      Shares slide as London-listed group announces ‘pause’ in vaccine manufacturing

    • Wednesday, 6 April, 2022
      LexPharmaceuticals sector
      Breast cancer: precision drugs make inroads against stubborn tumours Premium content

      New therapies replace a blunderbuss with a stiletto

    • Thursday, 17 March, 2022
      Covid-19 vaccines
      AstraZeneca prepared to ditch effort to secure US approval for Covid vaccine

      UK drugmaker’s R&D chief says abandoning market would have little impact

    • Thursday, 10 February, 2022
      Covid vaccine helps push AstraZeneca to record revenues

      UK pharmaceuticals group raises dividend for first time in a decade

    • Thursday, 6 January, 2022
      Covid-19 vaccines
      Covid vaccine makers face investor pressure over global access

      Asset managers call for pharma executive pay to be linked to equitable distribution of jabs

    • Thursday, 23 December, 2021
      LexCovid-19 vaccines
      Oxford/AstraZeneca vaccine: underdog provider needs to pass potency test Premium content

      The apparent efficacy of its booster against Omicron could shore up the jab’s shaky position among competitors

    • Thursday, 23 December, 2021
      Covid-19 vaccines
      AstraZeneca booster raises antibodies against Omicron less than Pfizer, study shows

      Pharma group says it is confident its Covid vaccine ‘should be given as a third dose booster’

    • Tuesday, 21 December, 2021
      Covid-19 vaccines
      Oxford and AstraZeneca developing Omicron-targeted version of vaccine

      Global health authorities have voiced concern that current jabs may afford less protection against variant

    • Monday, 20 December, 2021
      Covid-19 vaccines
      Covid boosters essential to back up Oxford/AstraZeneca jabs, new study shows

      Protection against severe disease begins to wane three months after second shot

    • Thursday, 2 December, 2021
      Covid-19 vaccines
      UK’s ‘mix and match’ booster jab strategy backed by new study

      Research shows mRNA vaccines from Pfizer and Moderna are by far most effective third doses

    • Tuesday, 23 November, 2021
      Pascal Soriot links AstraZeneca jab to low UK hospitalisations

      Chief executive says more data needed to explain Europe’s higher rate of admissions

    • Tuesday, 23 November, 2021
      AstraZeneca calls on UK to increase science investment

      Chair of pharma group says support will boost economy as it opens £1bn R&D campus in Cambridge

    • Tuesday, 23 November, 2021
      FT live news
      News updates from November 23: US to release 50m barrels of oil from reserves, thousands in England sign up for Covid booster, Apple sues Israeli spyware group NSO
    • Friday, 19 November, 2021
      News in-depth
      AstraZeneca’s vaccine hopes lie overseas as it runs out of road in UK

      British drugmaker’s exclusion from booster campaign is latest setback

    • Tuesday, 16 November, 2021
      Covid-19 vaccines
      Top scientist defends decision to sell AstraZeneca vaccine at a profit

      Pharma group partnership with Oxford university hits 2bn-dose milestone

    • Friday, 12 November, 2021
      AstraZeneca to take profits from Covid vaccine sales

      Pharma group to move away from non-profit model used during pandemic

    • Tuesday, 9 November, 2021
      AstraZeneca commits to vaccines business with new division

      Move comes despite Anglo-Swedish group’s non-profit Covid-19 jab suffering setbacks earlier this year

    • Monday, 25 October, 2021
      Covid-19 vaccines
      Covid vaccines associated with rare neurological complications, says study

      Researchers emphasise that adverse events following Pfizer and AstraZeneca jabs are extremely rare

    Previous page You are on page 1 Next page

    Topics related to Health & pharmaceuticals

    Be part of FT Community

    Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

    FT LiveGlobal Pharma and Biotech SummitDriving Investment and Innovation in Life Sciences
    Monday, 7th NovemberRoyal Lancaster Hotel, London
    Learn more about FT Community

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      • Cryptofinance
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Community
      • FT Live
      • FT Forums
      • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In